• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

循环miR-20a和miR-26a作为前列腺癌的生物标志物

Circulating miR-20a and miR-26a as Biomarkers in Prostate Cancer.

作者信息

Mohammadi Torbati Peyman, Asadi Fatemeh, Fard-Esfahani Pezhman

机构信息

Department of Pathology, Labbafi-Nezhad Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Department of Biochemistry, Pasteur Institute of Iran, Tehran, Iran. Email:

出版信息

Asian Pac J Cancer Prev. 2019 May 25;20(5):1453-1456. doi: 10.31557/APJCP.2019.20.5.1453.

DOI:10.31557/APJCP.2019.20.5.1453
PMID:31127907
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6857886/
Abstract

Objective: Circulating microRNAs (miRNAs), present in body fluids, have been considering importance as cancer biomarkers. The primary aim of this study was to assess whether circulatory miR-20a and miR-26a can be used as diagnostic biomarkers in prostate cancer (PCa). Methods: Relative expression miR-20a and miR-26a has been assessed in 40 patients with PCa and 40 non-cancerous volunteer. Sample Collection of patients was performed before and one week after prostatectomy. Total RNA was extracted from serum and miR-20a and miR-26a expressions were quantified by using Real-Time PCR method. Results: miR-20a was significantly up-regulated in pre-operation serum samples of PCa patients compared to the serum samples of non-cancerous controls, however, in post-operation samples no significant differences was showed. miR-26a level was not significantly decreased in pre and post-operation serum samples compared to the serum samples of controls. However, the expression level ratios of both miR-20a and miR-26a were insignificantly decreased when post-operation serum samples compared to pre-operation ones. Conclusion: Decrement of circulating miR-20a and miR-26a in patients after surgery may reflect the tumoral origin of those microRNAs and the results may use for tumor remnant monitoring after prostatectomy.

摘要

目的

存在于体液中的循环微RNA(miRNA)被认为是重要的癌症生物标志物。本研究的主要目的是评估循环miR-20a和miR-26a是否可作为前列腺癌(PCa)的诊断生物标志物。方法:对40例PCa患者和40名非癌志愿者的miR-20a和miR-26a相对表达进行了评估。在前列腺切除术前和术后一周对患者进行样本采集。从血清中提取总RNA,并使用实时荧光定量PCR方法对miR-20a和miR-26a的表达进行定量。结果:与非癌对照的血清样本相比,PCa患者术前血清样本中的miR-20a显著上调,然而,术后样本中未显示出显著差异。与对照的血清样本相比,术前和术后血清样本中的miR-26a水平均未显著降低。然而,与术前血清样本相比,术后血清样本中miR-20a和miR-26a的表达水平比值均无显著降低。结论:手术后患者循环miR-20a和miR-26a的减少可能反映了这些微RNA的肿瘤来源,其结果可用于前列腺切除术后肿瘤残留的监测。

相似文献

1
Circulating miR-20a and miR-26a as Biomarkers in Prostate Cancer.循环miR-20a和miR-26a作为前列腺癌的生物标志物
Asian Pac J Cancer Prev. 2019 May 25;20(5):1453-1456. doi: 10.31557/APJCP.2019.20.5.1453.
2
Circulating miR-26a and miR-21 as biomarkers for glioblastoma multiform.循环中的miR-26a和miR-21作为多形性胶质母细胞瘤的生物标志物。
Biotechnol Appl Biochem. 2019 Mar;66(2):261-265. doi: 10.1002/bab.1707. Epub 2018 Nov 19.
3
Circulating microRNAs in plasma before and after radical prostatectomy.根治性前列腺切除术前、后血浆中的循环 microRNAs。
Urol Oncol. 2019 Nov;37(11):814.e1-814.e7. doi: 10.1016/j.urolonc.2019.07.001. Epub 2019 Aug 14.
4
The correlation of circulating pro-angiogenic miRNAs' expressions with disease risk, clinicopathological features, and survival profiles in gastric cancer.循环促血管生成 miRNA 表达与胃癌发病风险、临床病理特征和生存状况的相关性。
Cancer Med. 2018 Aug;7(8):3773-3791. doi: 10.1002/cam4.1618. Epub 2018 Jul 12.
5
Serum microRNAs as biomarkers in patients undergoing prostate biopsy: results from a prospective multi-center study.血清 microRNAs 作为前列腺活检患者的生物标志物:一项前瞻性多中心研究的结果。
Anticancer Res. 2014 Feb;34(2):665-9.
6
Importance of miR-20a expression in prostate cancer tissue.miR-20a 在前列腺癌组织中的表达的重要性。
Anticancer Res. 2010 Sep;30(9):3579-83.
7
Circulating microRNA signature for the diagnosis of very high-risk prostate cancer.用于诊断极高风险前列腺癌的循环微小RNA特征
Proc Natl Acad Sci U S A. 2016 Sep 20;113(38):10655-60. doi: 10.1073/pnas.1611596113. Epub 2016 Sep 6.
8
Prognostic implications of tissue and serum levels of microRNA-128 in human prostate cancer.微小RNA-128的组织和血清水平对人类前列腺癌的预后影响
Int J Clin Exp Pathol. 2015 Jul 1;8(7):8394-401. eCollection 2015.
9
Circulating miRNAs as biomarkers for oral squamous cell carcinoma recurrence in operated patients.循环微小RNA作为口腔鳞状细胞癌手术患者复发的生物标志物
Oncotarget. 2017 Jan 31;8(5):8206-8214. doi: 10.18632/oncotarget.14143.
10
Identification of serum miRNAs by nano-quantum dots microarray as diagnostic biomarkers for early detection of non-small cell lung cancer.通过纳米量子点微阵列鉴定血清微小RNA作为早期检测非小细胞肺癌的诊断生物标志物。
Tumour Biol. 2016 Jun;37(6):7777-84. doi: 10.1007/s13277-015-4608-3. Epub 2015 Dec 22.

引用本文的文献

1
MicroRNA in prostate cancer: from biogenesis to applicative potential.微小 RNA 在前列腺癌中的作用:从生物发生到应用潜力。
BMC Urol. 2024 Nov 6;24(1):244. doi: 10.1186/s12894-024-01634-1.
2
miR-26a is a Key Therapeutic Target with Enormous Potential in the Diagnosis and Prognosis of Human Disease.miR-26a 是人类疾病诊断和预后的关键治疗靶点,具有巨大的潜力。
Curr Med Chem. 2024;31(18):2550-2570. doi: 10.2174/0109298673271808231116075056.
3
Current advances of liquid biopsies in prostate cancer: Molecular biomarkers.液体活检在前列腺癌中的当前进展:分子生物标志物

本文引用的文献

1
Change of Circulating and Tissue-Based miR-20a in Human Cancers and Associated Prognostic Implication: A Systematic Review and Meta-Analysis.循环和组织 miR-20a 在人类癌症中的变化及其相关预后意义:系统评价和荟萃分析。
Biomed Res Int. 2018 Nov 25;2018:6124927. doi: 10.1155/2018/6124927. eCollection 2018.
2
Circulating miR-26a and miR-21 as biomarkers for glioblastoma multiform.循环中的miR-26a和miR-21作为多形性胶质母细胞瘤的生物标志物。
Biotechnol Appl Biochem. 2019 Mar;66(2):261-265. doi: 10.1002/bab.1707. Epub 2018 Nov 19.
3
MicroRNAs as prognostic markers in prostate cancer.
Mol Ther Oncolytics. 2023 Jul 19;30:27-38. doi: 10.1016/j.omto.2023.07.004. eCollection 2023 Sep 21.
4
The potential of cell-free and exosomal microRNAs as biomarkers in liquid biopsy in patients with prostate cancer.无细胞和外泌体 microRNAs 作为前列腺癌患者液体活检生物标志物的潜力。
J Cancer Res Clin Oncol. 2022 Oct;148(10):2893-2910. doi: 10.1007/s00432-022-04213-9. Epub 2022 Aug 4.
5
microRNA-26a represses pancreatic cancer cell malignant behaviors by targeting E2F7.微小RNA-26a通过靶向E2F7抑制胰腺癌细胞的恶性行为。
Discov Oncol. 2021 Nov 27;12(1):55. doi: 10.1007/s12672-021-00448-z.
6
Regulation of Neuroendocrine-like Differentiation in Prostate Cancer by Non-Coding RNAs.非编码RNA对前列腺癌神经内分泌样分化的调控
Noncoding RNA. 2021 Dec 2;7(4):75. doi: 10.3390/ncrna7040075.
7
Identification of canine circulating miRNAs as tumor biospecific markers using Next-Generation Sequencing and Q-RT-PCR.利用新一代测序和定量逆转录聚合酶链反应鉴定犬循环miRNA作为肿瘤生物特异性标志物
Biochem Biophys Rep. 2021 Aug 19;28:101106. doi: 10.1016/j.bbrep.2021.101106. eCollection 2021 Dec.
8
Overexpression of miR-20a-5p in Tumor Epithelium Is an Independent Negative Prognostic Indicator in Prostate Cancer-A Multi-Institutional Study.肿瘤上皮中miR-20a-5p的过表达是前列腺癌的独立阴性预后指标——一项多机构研究
Cancers (Basel). 2021 Aug 14;13(16):4096. doi: 10.3390/cancers13164096.
9
Prognostic Value of miR-1826 in Prostate Cancer and Its Regulatory Effect on Tumor Progression.miR-1826在前列腺癌中的预后价值及其对肿瘤进展的调节作用
Onco Targets Ther. 2021 Aug 13;14:4467-4475. doi: 10.2147/OTT.S295125. eCollection 2021.
10
Serum MicroRNA-137 Serves as a Novel Biomarker for Cerebral Atherosclerosis Diagnosis and Cerebrovascular Event Prediction.血清 microRNA-137 可作为脑动脉粥样硬化诊断和脑血管事件预测的新型生物标志物。
J Cardiovasc Pharmacol. 2021 Jun 1;78(2):302-307. doi: 10.1097/FJC.0000000000001058.
微小 RNA 作为前列腺癌的预后标志物。
Prostate. 2019 Feb;79(3):265-271. doi: 10.1002/pros.23731. Epub 2018 Oct 21.
4
A study of circulating microRNAs identifies a new potential biomarker panel to distinguish aggressive prostate cancer.一项关于循环 microRNAs 的研究确定了一个新的潜在生物标志物panel,可用于区分侵袭性前列腺癌。
Carcinogenesis. 2018 Apr 5;39(4):556-561. doi: 10.1093/carcin/bgy025.
5
Circulating microRNAs in plasma as potential biomarkers for the early detection of prostate cancer.血浆中的循环微RNA作为前列腺癌早期检测的潜在生物标志物。
Prostate. 2018 May;78(6):411-418. doi: 10.1002/pros.23485. Epub 2018 Jan 31.
6
High circulating miR-18a, miR-20a, and miR-92a expression correlates with poor prognosis in patients with non-small cell lung cancer.高循环 miR-18a、miR-20a 和 miR-92a 的表达与非小细胞肺癌患者的不良预后相关。
Cancer Med. 2018 Jan;7(1):21-31. doi: 10.1002/cam4.1238. Epub 2017 Dec 21.
7
Downregulated microRNA-26a modulates prostate cancer cell proliferation and apoptosis by targeting COX-2.下调的微小RNA-26a通过靶向环氧化酶-2调节前列腺癌细胞的增殖和凋亡。
Oncol Lett. 2016 Nov;12(5):3397-3402. doi: 10.3892/ol.2016.5070. Epub 2016 Aug 31.
8
Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status.基于血液的前列腺良性增生与前列腺癌的鉴别诊断:miRNA作为独立于PSA水平、Gleason评分或TNM分期的生物标志物来源
Tumour Biol. 2016 Aug;37(8):10177-85. doi: 10.1007/s13277-016-4883-7. Epub 2016 Jan 29.
9
PSA and beyond: alternative prostate cancer biomarkers.前列腺特异性抗原及其他:前列腺癌替代生物标志物
Cell Oncol (Dordr). 2016 Apr;39(2):97-106. doi: 10.1007/s13402-016-0268-6. Epub 2016 Jan 20.
10
miR-26a suppresses tumour proliferation and metastasis by targeting metadherin in triple negative breast cancer.微小RNA-26a通过靶向三阴性乳腺癌中的黏附素抑制肿瘤增殖和转移。
Cancer Lett. 2015 Feb 1;357(1):384-392. doi: 10.1016/j.canlet.2014.11.050. Epub 2014 Nov 27.